NO304317B1 - FremgangsmÕte for fremstilling av et terapeutisk aktivt, endret pneumolysin, samt et rekombinant plasmid og en vertscelle - Google Patents

FremgangsmÕte for fremstilling av et terapeutisk aktivt, endret pneumolysin, samt et rekombinant plasmid og en vertscelle Download PDF

Info

Publication number: NO304317B1
Authority: NO; Norway
Prior art keywords: pneumolysin; altered; trp; phe; wild
Prior art date: 1988-12-16

Application number

NO912226A

Other languages

English (en)

Norwegian (no)

Other versions

NO912226L (no

NO912226D0 (no

Inventor

James Cleland Paton

David John Hansman

Graham John Boulnois

Peter William Andrew

Timothy John Mitchell

John Arthur Walker

Original Assignee

Nederlanden Staat

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-16

Filing date

1991-06-11

Publication date

1998-11-30

1991-06-11 Application filed by Nederlanden Staat filed Critical Nederlanden Staat

1991-06-11 Publication of NO912226D0 publication Critical patent/NO912226D0/no

1991-07-25 Publication of NO912226L publication Critical patent/NO912226L/no

1998-11-30 Publication of NO304317B1 publication Critical patent/NO304317B1/no

Links

101710183389 Pneumolysin Proteins 0.000 title claims abstract description 76
238000000034 method Methods 0.000 title claims description 12
239000013612 plasmid Substances 0.000 title claims description 7
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 13
230000028993 immune response Effects 0.000 claims abstract description 7
231100000252 nontoxic Toxicity 0.000 claims abstract description 7
230000003000 nontoxic effect Effects 0.000 claims abstract description 7
230000035772 mutation Effects 0.000 claims description 13
108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
230000002829 reductive effect Effects 0.000 claims description 10
230000027455 binding Effects 0.000 claims description 8
239000013604 expression vector Substances 0.000 claims description 6
230000000295 complement effect Effects 0.000 claims description 5
230000001105 regulatory effect Effects 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
239000003550 marker Substances 0.000 claims description 4
238000013518 transcription Methods 0.000 claims description 3
230000035897 transcription Effects 0.000 claims description 3
238000013519 translation Methods 0.000 claims description 3
230000002103 transcriptional effect Effects 0.000 claims description 2
150000004676 glycans Chemical class 0.000 abstract description 24
229920001282 polysaccharide Polymers 0.000 abstract description 24
239000005017 polysaccharide Substances 0.000 abstract description 24
229960005486 vaccine Drugs 0.000 abstract description 22
238000006467 substitution reaction Methods 0.000 abstract description 7
241001465754 Metazoa Species 0.000 abstract description 2
108090000623 proteins and genes Proteins 0.000 description 15
230000002949 hemolytic effect Effects 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 10
206010035664 Pneumonia Diseases 0.000 description 8
210000004027 cell Anatomy 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 6
241000193998 Streptococcus pneumoniae Species 0.000 description 5
239000000463 material Substances 0.000 description 5
NGXDNMNOQDVTRL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(4-azido-2-nitroanilino)hexanoate Chemical compound [O-][N+](=O)C1=CC(N=[N+]=[N-])=CC=C1NCCCCCC(=O)ON1C(=O)CCC1=O NGXDNMNOQDVTRL-UHFFFAOYSA-N 0.000 description 4
208000035109 Pneumococcal Infections Diseases 0.000 description 4
239000000427 antigen Substances 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
230000024203 complement activation Effects 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
231100000765 toxin Toxicity 0.000 description 4
239000003053 toxin Substances 0.000 description 4
108700012359 toxins Proteins 0.000 description 4
108020004414 DNA Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000006722 reduction reaction Methods 0.000 description 3
201000009890 sinusitis Diseases 0.000 description 3
238000002741 site-directed mutagenesis Methods 0.000 description 3
239000001488 sodium phosphate Substances 0.000 description 3
229910000162 sodium phosphate Inorganic materials 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
238000000108 ultra-filtration Methods 0.000 description 3
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
208000031729 Bacteremia Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
206010033078 Otitis media Diseases 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000000376 reactant Substances 0.000 description 2
239000013598 vector Substances 0.000 description 2
102100039182 Ankyrin repeat and protein kinase domain-containing protein 1 Human genes 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
201000001178 Bacterial Pneumonia Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
108010074051 C-Reactive Protein Proteins 0.000 description 1
102100032752 C-reactive protein Human genes 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
101100491147 Homo sapiens ANKK1 gene Proteins 0.000 description 1
101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
206010027253 Meningitis pneumococcal Diseases 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
238000005273 aeration Methods 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
-1 cyanoborohydride Chemical compound 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
208000004593 pneumococcal meningitis Diseases 0.000 description 1
229940049548 pneumovax Drugs 0.000 description 1
231100000654 protein toxin Toxicity 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
238000009877 rendering Methods 0.000 description 1
102220001414 rs121907905 Human genes 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000000527 sonication Methods 0.000 description 1
208000022218 streptococcal pneumonia Diseases 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
229940118376 tetanus toxin Drugs 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000003396 thiol group Chemical class [H]S* 0.000 description 1
238000011282 treatment Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Exchange Systems With Centralized Control (AREA)
Manufacturing Of Steel Electrode Plates (AREA)
Current-Collector Devices For Electrically Propelled Vehicles (AREA)

NO912226A 1988-12-16 1991-06-11 FremgangsmÕte for fremstilling av et terapeutisk aktivt, endret pneumolysin, samt et rekombinant plasmid og en vertscelle NO304317B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPJ198988		1988-12-16
PCT/AU1989/000539 WO1990006951A1 (en)	1988-12-16	1989-12-15	Pneumolysin mutants and pneumococcal vaccines made therefrom

Publications (3)

Publication Number	Publication Date
NO912226D0 NO912226D0 (no)	1991-06-11
NO912226L NO912226L (no)	1991-07-25
NO304317B1 true NO304317B1 (no)	1998-11-30

Family

ID=3773589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO912226A NO304317B1 (no)	1988-12-16	1991-06-11	FremgangsmÕte for fremstilling av et terapeutisk aktivt, endret pneumolysin, samt et rekombinant plasmid og en vertscelle

Country Status (15)

Country	Link
EP (1)	EP0449856B1 (de)
JP (1)	JP3237842B2 (de)
AT (1)	ATE205534T1 (de)
AU (1)	AU626961B2 (de)
BG (1)	BG51358A3 (de)
CA (1)	CA2005704C (de)
DE (1)	DE68929323T2 (de)
DK (1)	DK173629B1 (de)
ES (1)	ES2160570T3 (de)
FI (1)	FI103122B1 (de)
HU (1)	HUT58804A (de)
MC (1)	MC2178A1 (de)
NO (1)	NO304317B1 (de)
RU (1)	RU2121481C1 (de)
WO (1)	WO1990006951A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6716432B1 (en) *	1988-12-16	2004-04-06	James Cleland Paton	Pneumolysin mutants and pneumococcal vaccines made therefrom
CA2059693C (en) *	1991-01-28	2003-08-19	Peter J. Kniskern	Polysaccharide antigens from streptococcus pneumoniae
US5391712A (en) *	1991-08-30	1995-02-21	Beckman Instruments, Inc.	Non-hemolytic streptolysin O variants
US5928900A (en) *	1993-09-01	1999-07-27	The Rockefeller University	Bacterial exported proteins and acellular vaccines based thereon
EP0687688A1 (de) *	1993-12-17	1995-12-20	Universidad De Oviedo	Antikörper gegen neumolysin und ihre verwendung
US8791237B2 (en)	1994-11-08	2014-07-29	The Trustees Of The University Of Pennsylvania	Compositions and methods for treatment of non-hodgkins lymphoma
AU740956B2 (en) *	1997-07-21	2001-11-15	Baxter Healthcare Sa	Modified immunogenic pneumolysin compositions as vaccines
GB9906437D0 (en) *	1999-03-19	1999-05-12	Smithkline Beecham Biolog	Vaccine
JP2002539273A (ja)	1999-03-19	2002-11-19	スミスクラインビーチャムバイオロジカルズソシエテアノニム	ワクチン
GB9918319D0 (en)	1999-08-03	1999-10-06	Smithkline Beecham Biolog	Vaccine composition
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
ATE439372T1 (de)	2000-10-27	2009-08-15	Novartis Vaccines & Diagnostic	Nukleinsäuren und proteine von gruppen a und b- streptokokken
GB0109297D0 (en)	2001-04-12	2001-05-30	Glaxosmithkline Biolog Sa	Vaccine
CA2493124C (en)	2002-08-02	2014-04-29	Glaxosmithkline Biologicals S.A.	Vaccine
MXPA05004528A (es)	2002-11-01	2005-07-26	Glaxosmithkline Biolog Sa	Composicion inmunogenica.
CN100443116C (zh)	2002-11-07	2008-12-17	新纳几美国公司	治疗或预防肺炎球菌感染的组合物及其用途
PT1601689E (pt)	2003-03-13	2008-01-04	Glaxosmithkline Biolog Sa	Processo de purificação para citolisina bacteriana
JP4875490B2 (ja)	2003-07-31	2012-02-15	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物
US8945589B2 (en)	2003-09-15	2015-02-03	Novartis Vaccines And Diagnostics, Srl	Immunogenic compositions for Streptococcus agalactiae
ATE474595T1 (de)	2003-10-02	2010-08-15	Glaxosmithkline Biolog Sa	B. pertussis antigene und ihre verwendung bei der vakzinierung
CA2555803A1 (en) *	2004-02-13	2005-08-27	Sanofi Pasteur Limited	Pneumolysin derivatives
WO2005108419A1 (en) *	2004-05-07	2005-11-17	Lea-Ann Kirkham	Mutant cholesterol-binding cytolysin proteins
GB0410220D0 (en) *	2004-05-07	2004-06-09	Kirkham Lea Ann	Mutant pneumolysin proteins
US20060165716A1 (en)	2004-07-29	2006-07-27	Telford John L	Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0421083D0 (en) *	2004-09-22	2004-10-27	Glaxosmithkline Biolog Sa	Purification process
WO2006042027A2 (en)	2004-10-08	2006-04-20	Novartis Vaccines And Diagnostics Inc.	Immunogenic and therapeutic compositions for streptococcus pyogenes
GB0505996D0 (en)	2005-03-23	2005-04-27	Glaxosmithkline Biolog Sa	Fermentation process
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
BRPI0620460B8 (pt)	2005-12-22	2021-05-25	Glaxosmithkline Biologicals Sa	uso de composição imunogênica para bebês, e, processo para produzir uma vacina
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
EP1973933B1 (de)	2006-01-17	2020-06-24	Forsgren, Arne	Neues oberflächenexponiertes haemophilus influenzae-protein (protein e; pe)
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
KR101378872B1 (ko)	2006-09-26	2014-04-11	인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이)	합성 애주번트를 함유하는 백신 조성물
ES2397714T3 (es)	2006-10-12	2013-03-08	Glaxosmithkline Biologicals S.A.	Vacuna que comprende un adyuvante de emulsión de aceite en agua
EP2433648A3 (de)	2006-10-12	2012-04-04	GlaxoSmithKline Biologicals S.A.	Impfstoff mit einem Öl-in-wasser-emulsionshilfsstoff
CA2679410C (en)	2007-03-02	2017-01-17	Glaxosmithkline Biologicals S.A.	Novel method and compositions
US9717788B2 (en)	2007-03-02	2017-08-01	Glaxosmithkline Biologicals Sa	Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
CA2683748C (en) *	2007-04-13	2016-02-16	The Board Of Regents Of The University Of Oklahoma	Mutants of cholesterol-dependent cytolysins and uses thereof
BRPI0813644B8 (pt) *	2007-06-26	2021-05-25	Glaxosmithkline Biologicals Sa	composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
CA2699513C (en)	2007-09-12	2018-03-13	Novartis Ag	Gas57 mutant antigens and gas57 antibodies
BRPI0821240B8 (pt)	2007-12-21	2022-10-04	Novartis Ag	formas mutantes de estreptolisina o
US20120164178A1 (en)	2008-04-16	2012-06-28	Ballou Jr William Ripley	Vaccine
GB0815872D0 (en)	2008-09-01	2008-10-08	Pasteur Institut	Novel method and compositions
CN102712680B (zh) *	2008-12-24	2016-06-22	荷兰王国卫生福利和运动部国家公共卫生和环境研究所	修饰的肺炎链球菌溶血素(ply)多肽
US20120064103A1 (en)	2009-03-24	2012-03-15	Novartis Ag	Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
SI2437753T1 (sl)	2009-06-05	2016-12-30	Infectious Disease Research Institute	Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
WO2011030218A1 (en)	2009-09-10	2011-03-17	Novartis Ag	Combination vaccines against respiratory tract diseases
WO2011075823A1 (en) *	2009-12-22	2011-06-30	Sanofi Pasteur Limited	Immunogenic compositions
CN102939105B (zh)	2009-12-22	2016-11-16	赛诺菲巴斯德有限公司	免疫原性组合物和相关的方法
CA2792679C (en)	2010-03-09	2019-11-12	Mucosal Vaccine Thechnologies Llc	A novel mucosal vaccination approach for herpes simplex virus type-2
GB201003924D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Immunogenic composition
EP2544714A1 (de)	2010-03-10	2013-01-16	GlaxoSmithKline Biologicals S.A.	Impfstoffzusammensetzung
NZ602892A (en)	2010-04-13	2014-08-29	Celldex Therapeutics Inc	Antibodies that bind human cd27 and uses thereof
GB201015132D0 (en)	2010-09-10	2010-10-27	Univ Bristol	Vaccine composition
WO2012072769A1 (en)	2010-12-01	2012-06-07	Novartis Ag	Pneumococcal rrgb epitopes and clade combinations
GB201022007D0 (en)	2010-12-24	2011-02-02	Imp Innovations Ltd	DNA-sensor
US9181308B2 (en)	2011-03-28	2015-11-10	St. Jude Children's Research Hospital	Methods and compositions employing immunogenic fusion proteins
AU2012243039B2 (en)	2011-04-08	2017-07-13	Immune Design Corp.	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
SG194733A1 (en)	2011-05-17	2013-12-30	Glaxosmithkline Biolog Sa	Vaccine against streptococcus pneumoniae
CN110339160A (zh)	2012-02-07	2019-10-18	传染性疾病研究院	包含tlr4激动剂的改进佐剂制剂及其使用方法
CN104519910B (zh)	2012-03-07	2017-05-03	诺华股份有限公司	肺炎链球菌抗原的含佐剂制剂
PT2850431T (pt)	2012-05-16	2018-07-23	Immune Design Corp	Vacinas para hsv-2
DK2941269T3 (da)	2013-01-07	2021-01-11	Mucosal Vaccine Tech Llc	Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner
US9802987B2 (en)	2013-03-08	2017-10-31	Pfizer Inc.	Immunogenic fusion polypeptides
EP3711768A1 (de)	2013-04-18	2020-09-23	Immune Design Corp.	Gla-monotherapie zur verwendung in der krebsbehandlung
US11207396B2 (en)	2013-05-17	2021-12-28	The Board Of Regents Of The University Of Texas System	Immunization to protect against adverse cardiac events relating to pneumococcal infection
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
IL310015B2 (en)	2013-12-31	2026-02-01	Access To Advanced Health Inst	Single vial formulation
US9815886B2 (en)	2014-10-28	2017-11-14	Adma Biologics, Inc.	Compositions and methods for the treatment of immunodeficiency
ES2993430T3 (en)	2014-11-21	2024-12-30	Univ Oklahoma	Pneumolysin mutants and methods of use thereof
EP3268037B1 (de)	2015-03-09	2022-08-31	Celldex Therapeutics, Inc.	Cd27 agonists
GB201518684D0 (en)	2015-10-21	2015-12-02	Glaxosmithkline Biolog Sa	Vaccine
WO2017176076A1 (en)	2016-04-06	2017-10-12	Ewha University - Industry Collaboration Foundation	A peptide with ability to penetrate cell membrane
JP7038064B2 (ja)	2016-04-18	2022-03-17	セルデックスセラピューティクスインコーポレイテッド	ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
EP4112638A1 (de)	2016-05-16	2023-01-04	Access to Advanced Health Institute	Formulierung mit tlr-agonist und verfahren zur verwendung
IL263030B2 (en)	2016-05-16	2024-11-01	Access To Advanced Health Inst	Pegylated liposomes and methods of use
KR102748354B1 (ko)	2016-06-01	2024-12-31	액세스 투 어드밴스드 헬스 인스티튜트	사이징제를 함유하는 나노명반 입자
GB201610599D0 (en)	2016-06-17	2016-08-03	Glaxosmithkline Biologicals Sa	Immunogenic Composition
US10259865B2 (en)	2017-03-15	2019-04-16	Adma Biologics, Inc.	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102673794B1 (ko)	2017-06-15	2024-06-11	액세스 투 어드밴스드 헬스 인스티튜트	나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
GB201711635D0 (en)	2017-07-19	2017-08-30	Glaxosmithkline Biologicals Sa	Immunogenic composition
CN111315406A (zh)	2017-09-08	2020-06-19	传染病研究所	包括皂苷的脂质体调配物及其使用方法
WO2019204462A2 (en)	2018-04-17	2019-10-24	Celldex Therapeutics, Inc.	Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
WO2020123444A1 (en)	2018-12-11	2020-06-18	Celldex Therapeutics, Inc.	Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
US20220054632A1 (en)	2018-12-12	2022-02-24	Glaxosmithkline Biologicals Sa	Modified carrier proteins for o-linked glycosylation
BR112021023726A2 (pt)	2019-05-25	2022-02-15	Infectious Disease Res Inst	Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
EP3900739A1 (de)	2020-04-21	2021-10-27	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
EP3919076A1 (de)	2020-06-02	2021-12-08	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Synthetische oligosaccharidimpfstoffe gegen streptococcus pneumoniae mit mikropartikel-adjuvans-formulierungen
CA3174411A1 (en)	2020-09-04	2022-03-10	Ryan M. Kramer	Co-lyophilized rna and nanostructured lipid carrier
EP4320159A1 (de)	2021-04-09	2024-02-14	Celldex Therapeutics, Inc.	Antikörper gegen ilt4, bispezifische anti-ilt4/pd-l1-antikörper und verwendungen davon
WO2023077521A1 (en)	2021-11-08	2023-05-11	Celldex Therapeutics, Inc	Anti-ilt4 and anti-pd-1 bispecific constructs
AU2022391752A1 (en)	2021-11-18	2024-06-13	Matrivax, Inc.	Immunogenic fusion protein compositions and methods of use thereof
EP4583841A1 (de)	2022-09-09	2025-07-16	Access to Advanced Health Institute	Immunogene impfstoffzusammensetzung mit einem saponin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2495939B1 (fr) *	1980-12-11	1985-10-11	Merieux Inst	Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies
ATE207960T1 (de) *	1993-09-03	2001-11-15	Nestle Sa	Bacteriocine aus streptococcus thermophilus

1989
- 1989-12-15 MC MC89@@D patent/MC2178A1/xx unknown
- 1989-12-15 HU HU90433A patent/HUT58804A/hu unknown
- 1989-12-15 WO PCT/AU1989/000539 patent/WO1990006951A1/en not_active Ceased
- 1989-12-15 AU AU47564/90A patent/AU626961B2/en not_active Expired
- 1989-12-15 RU SU4895772A patent/RU2121481C1/ru active
- 1989-12-15 JP JP50093590A patent/JP3237842B2/ja not_active Expired - Lifetime
- 1989-12-15 AT AT90900035T patent/ATE205534T1/de not_active IP Right Cessation
- 1989-12-15 EP EP90900035A patent/EP0449856B1/de not_active Expired - Lifetime
- 1989-12-15 DE DE68929323T patent/DE68929323T2/de not_active Expired - Lifetime
- 1989-12-15 ES ES90900035T patent/ES2160570T3/es not_active Expired - Lifetime
- 1989-12-15 CA CA002005704A patent/CA2005704C/en not_active Expired - Lifetime
1991
- 1991-06-11 NO NO912226A patent/NO304317B1/no not_active IP Right Cessation
- 1991-06-12 BG BG094614A patent/BG51358A3/bg unknown
- 1991-06-14 FI FI912878A patent/FI103122B1/fi active
- 1991-06-14 DK DK199101155A patent/DK173629B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO1990006951A1 (en)	1990-06-28
DE68929323T2 (de)	2002-04-18
NO912226L (no)	1991-07-25
FI912878A0 (fi)	1991-06-14
ATE205534T1 (de)	2001-09-15
MC2178A1 (fr)	1992-05-22
DK115591D0 (da)	1991-06-14
NO912226D0 (no)	1991-06-11
FI103122B (fi)	1999-04-30
AU626961B2 (en)	1992-08-13
BG51358A3 (bg)	1993-04-15
CA2005704C (en)	2003-02-11
EP0449856B1 (de)	2001-09-12
DE68929323D1 (de)	2001-10-18
EP0449856A4 (en)	1992-05-20
AU4756490A (en)	1990-07-10
EP0449856A1 (de)	1991-10-09
CA2005704A1 (en)	1990-06-16
ES2160570T3 (es)	2001-11-16
DK173629B1 (da)	2001-05-14
RU2121481C1 (ru)	1998-11-10
JPH04503948A (ja)	1992-07-16
HUT58804A (en)	1992-03-30
FI103122B1 (fi)	1999-04-30
DK115591A (da)	1991-08-14
JP3237842B2 (ja)	2001-12-10

Legal Events

Date	Code	Title	Description
2010-01-18	MK1K	Patent expired

Publication	Publication Date	Title
EP0449856B1 (de)	2001-09-12	Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
ES2642076T3 (es)	2017-11-15	Composiciones inmunogénicas de antígenos de Staphylococcus aureus
US7585669B2 (en)	2009-09-08	Compositions and methods for treating or preventing pneumococcal infection
ES2360296T3 (es)	2011-06-02	Vacunas y proteínas de setreptococcus pneumoniae.
KR20190066032A (ko)	2019-06-12	폴리사카라이드-단백질 접합체를 포함하는 다가 폐렴구균 백신 조성물
US6716432B1 (en)	2004-04-06	Pneumolysin mutants and pneumococcal vaccines made therefrom
AU2018285857B2 (en)	2022-10-06	Immunogenic compositions comprising Staphylococcus aureus leukocidin lukA and lukB derived polypeptides
EP0527724B1 (de)	1997-08-27	Zubereitungen und behandlungen von pneumonia in tieren
CN112118865B (zh)	2025-03-28	肺炎球菌表面蛋白a(pspa)的表达
CN100999548B (zh)	2010-09-08	白喉毒素突变体crm197及其制备方法
US6887480B1 (en)	2005-05-03	Streptococcus pneumoniae proteins and vaccines
JP4749641B2 (ja)	2011-08-17	ワクチン用の肺炎球菌タンパク質の相同体および断片
US11826412B2 (en)	2023-11-28	Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
Chen et al.	1999	A nontoxic Pseudomonas exotoxin A induces active immunity and passive protective antibody against Pseudomonas exotoxin A intoxication
GR1010289B (el)	2022-08-29	Τοξοειδη πεπτιδια που προερχονται απο διαλυτη σε φαινολη μοδουλινη, τοξινη δελτα, υπεραντιγονα και συντηξεις αυτων
NZ626762B2 (en)	2016-11-01	Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
NZ626762A (en)	2016-07-29	Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides